Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Up 521.5% in June

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a large growth in short interest in the month of June. As of June 15th, there was short interest totalling 500,300 shares, a growth of 521.5% from the May 31st total of 80,500 shares. Approximately 3.0% of the shares of the company are short sold. Based on an average trading volume of 216,400 shares, the days-to-cover ratio is currently 2.3 days.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GANX shares. HC Wainwright reiterated a “buy” rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Tuesday, May 28th. Oppenheimer reissued an “outperform” rating and set a $9.00 price target on shares of Gain Therapeutics in a research report on Tuesday, April 23rd. Finally, Chardan Capital reissued a “buy” rating and set a $6.00 price target on shares of Gain Therapeutics in a research report on Wednesday, March 27th.

Gain Therapeutics Stock Down 0.4 %

NASDAQ GANX traded down $0.01 on Friday, reaching $1.25. The stock had a trading volume of 400,975 shares, compared to its average volume of 199,644. The business has a 50 day moving average price of $2.36 and a 200 day moving average price of $3.29. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 0.05. Gain Therapeutics has a 1 year low of $1.20 and a 1 year high of $5.33. The company has a market capitalization of $22.47 million, a price-to-earnings ratio of -0.82 and a beta of 0.47.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. On average, analysts forecast that Gain Therapeutics will post -1.11 EPS for the current fiscal year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.